Thrombosis and Bleeding in Philadelphia Negative Myeloproliferative Neoplasia: Incidences and Risk Factors

Objective: Thrombohemorrhagic events developing in the Philadelphia neg-ative myeloproliferative neoplasms may worsen the clinical course of the dis-ease and increase the morbidity and mortality. The aim of this study is to as-sess critical risk factors of the hemostatic complications in myeloprolifera-tive neoplasms.Materials and Methods: The patients who were diagnosed as myeloprolif-erative neoplasm based on world health organization 2016 criteria are in-cluded into the study. The categorical and continuous data were compared with Chi-square and independent sample t-test. The statistical significance threshold was considered as p

___

Martin K. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis. Current hemato-logic malignancy reports 2017;12:5389-96.

Baş B, Köksal A, Özatll D, Haznedaroglu I, Koşar A, Büyükaşik Y, Ozcebe O, Dündar S. Thrombosis and hemor-rhage in chronic myeloproliferative disorders. Clinical and Applied Thrombosis/Hemostasis 1999;5:4282-4.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert J. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. Journal of hematology & on-cology 2016;9:118.

Norris D, Stone J. WHO classification of tumours of haema-topoietic and lymphoid tissues. Geneva: WHO 2008.

Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood re-views 2010;24:6227-32.

Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM. Incidence and risk factors for bleeding in 1104 pa-tients with essential thrombocythemia or prefibrotic my-elofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012;26:4716.

Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complica-tions in myeloproliferative disorders. Annals of hematolo-g y 19 91; 63:2101- 6 .

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011:blood-2011-02-339002.

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I. Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). Blood 2012:blood-2012-07-444067.

Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Mico C, Vannucchi AM, Antonioli E. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a ret-rospective survey. Blood 2008;111:2666-71.

Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Estrogen‐based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer 2006;106:112406-11.

De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, Chiusolo P, Sica S, Leone G. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombot-ic risk among patients with essential thrombocythemia. Haematologica 2009;94(5):733-7. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi A, Rodeghiero F, Randi M, Vaidya R, Cazzola M, Rambaldi A. Survival and prognosis among 1545 patients with con-temporary polycythemia vera: an international study.